Cartalax
Status
No approved product. No FDA-approved labeling exists. Not an approved medicine in the United States; status in other countries, including Russia and neighbouring states, was not verified here.
What it is
A short peptide studied in Russian work for connective tissue.
What published research measured
A synthetic tripeptide from the Khavinson bioregulator programme at the St Petersburg Institute of Bioregulation and Gerontology, proposed to act on cartilage and connective tissue. The evidence sits within a research tradition that is almost entirely single-institute and largely Russian-language, with very little independent replication outside that network. This entry does not cite a ClinicalTrials.gov registration for this compound or published human efficacy data in English-language peer-reviewed literature. The programme's central proposal — that peptides two to four residues long enter the nucleus and regulate specific genes by binding promoter DNA — remains outside mainstream structural biology and has not been independently confirmed.
Source
Khavinson programme preclinical publications
Sources
No linked primary source is on file for this entry yet.
Educational use only, never medical advice. No doses.